MedTrace Logo

Treating Primary Sclerosing Cholangitis and Biliary Atresia With Vancomycin

NCT02137668 · Status: RECRUITING · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 200

Last updated 2016-11-15

No results posted yet for this study

Summary

The purpose of this study is twofold. First, is to determine whether vancomycin is effective in the early treatment of Biliary Atresia (BA) and Primary Sclerosing Cholangitis (PSC), and if so, by what mechanism. Secondly, to characterize human intestinal microbial communities and their interactions with the host.

Conditions

  • Primary Sclerosing Cholangitis
  • Biliary Atresia

Interventions

DRUG

Oral Vancomycin

Oral Vancomycin is given to PSC or BA participants

Sponsors & Collaborators

  • Sacramento Pediatric Gastroenterology

    lead OTHER

Principal Investigators

  • Yinka Davies, M.D. · Sacramento Pediatric Gastroenterology

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
2 Weeks
Max Age
40 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2010-07-31
Primary Completion
2018-05-31
Completion
2028-07-31

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02137668 on ClinicalTrials.gov